H.C. Wainwright raised the firm’s price target on Tyra Biosciences to $17 from $15 and keeps a Buy rating on the shares. The analyst says BridgeBio’s data mitigates risk of TYRA-300 clinical development in achondroplasia. The firm increased its probability of success for TYRA-300 in achondroplasia to 35% from 30%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TYRA:
- Opco views BridgeBio data as good news for Tyra Biosciences
- Tyra Biosciences price target raised to $15 from $12 at H.C. Wainwright
- Tyra Biosciences price target raised to $25 from $17 at Oppenheimer
- Tyra Biosciences expands development of TYRA-300 into achondroplasia
- Tyra Biosciences initiated with an Outperform at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue